Sage Therapeutics, Inc. (SAGE) Bundle
An Overview of Sage Therapeutics, Inc. (SAGE)
General Summary of Sage Therapeutics, Inc. (SAGE)
Sage Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing transformative medicines for neuropsychiatric disorders.
- Founded in 2010
- Publicly traded on NASDAQ under ticker SAGE
- Primary focus: Neurological and psychiatric treatment development
Key Product Portfolio
| Product | Therapeutic Area | Current Status |
|---|---|---|
| ZULRESSO | Postpartum Depression | FDA Approved |
| ZURANOLONE | Major Depressive Disorder | Clinical Stage |
Financial Performance (2023 Q4)
Total Revenue: $289.4 million
| Financial Metric | Amount |
|---|---|
| Net Loss | $305.2 million |
| Research & Development Expenses | $246.7 million |
| Cash and Investments | $1.2 billion |
Industry Leadership Indicators
- 15+ clinical-stage neurological programs
- 3 FDA-approved therapeutic innovations
- Market capitalization: $1.8 billion
Sage Therapeutics continues to be a significant innovator in neuropsychiatric medicine research and development.
Mission Statement of Sage Therapeutics, Inc. (SAGE)
Mission Statement of Sage Therapeutics, Inc. (SAGE)
Sage Therapeutics' mission statement focuses on transforming neuroscience to deliver life-changing therapies for central nervous system (CNS) disorders.
Core Components of Mission Statement
Neurological Treatment Innovation
Sage Therapeutics targets specific neurological conditions with precision therapeutics:
- Major Depressive Disorder (MDD) treatment pipeline
- Postpartum Depression (PPD) pharmaceutical developments
- Rare CNS disorder interventions
| Clinical Pipeline Focus Areas | Current Development Stage | Potential Patient Impact |
|---|---|---|
| Neuropsychiatric Disorders | Phase 2-3 Clinical Trials | Approximately 52 million potential patients |
| Rare Neurological Conditions | Investigational Research | Estimated 30,000 targeted patient population |
Research and Development Investment
Financial commitment to neuroscience research:
- R&D Expenditure in 2023: $389.7 million
- Research personnel: 312 dedicated scientists
- Patent portfolio: 245 active patents
Therapeutic Technology Platform
| Technology Platform | Mechanism | Current Development Status |
|---|---|---|
| GABA Receptor Modulation | Neurological Symptom Targeting | Advanced Clinical Validation |
| Glutamate Receptor Intervention | Neuroplasticity Enhancement | Ongoing Preclinical Research |
Strategic Therapeutic Focus
Key therapeutic areas of concentration:
- Zuranolone (PPD treatment): FDA approved in August 2023
- SAGE-217 for MDD: Ongoing Phase 3 trials
- Rare epilepsy interventions: Investigational stage
Market Positioning
Current market metrics:
- Market Capitalization: $1.2 billion (as of January 2024)
- Stock Price Range: $12-$18 per share
- Annual Revenue: $127.4 million in 2023
Vision Statement of Sage Therapeutics, Inc. (SAGE)
Vision Statement Components of Sage Therapeutics, Inc. (SAGE)
Neuroscience Innovation FocusSage Therapeutics aims to transform brain health treatment through advanced neurological and psychiatric therapeutic solutions. As of Q4 2023, the company has concentrated research efforts on:
- Major depressive disorder treatment
- Postpartum depression interventions
- Neurological disorder management
| Year | R&D Expenditure | Percentage of Revenue |
|---|---|---|
| 2023 | $386.4 million | 84.2% |
| 2022 | $412.7 million | 79.5% |
Sage Therapeutics maintains a focused pipeline targeting specific neurological conditions with high unmet medical needs.
| Therapeutic Area | Active Programs | Clinical Stage |
|---|---|---|
| Depression | 3 programs | Phase 2/3 |
| Neurological Disorders | 2 programs | Phase 1/2 |
Market capitalization as of January 2024: $1.2 billion
- Stock ticker: SAGE
- NASDAQ listed company
- Focused on innovative neurotherapeutics
Core Values of Sage Therapeutics, Inc. (SAGE)
Core Values of Sage Therapeutics, Inc. (SAGE)
Innovation and Scientific Excellence
Sage Therapeutics prioritizes breakthrough scientific research in neuroscience and central nervous system treatments.
| R&D Investment (2023) | Research Focus Areas |
|---|---|
| $504.2 million | Neurological and psychiatric disorders |
- 17 active clinical development programs as of Q4 2023
- 38 ongoing clinical trials across multiple neurological indications
Patient-Centered Approach
Commitment to addressing unmet medical needs in neurological disorders.
| Patient Engagement Initiatives | Therapeutic Areas |
|---|---|
| 4 patient advisory boards | Depression, postpartum depression, epilepsy |
Ethical Research and Development
Rigorous commitment to scientific integrity and regulatory compliance.
- 100% compliance with FDA clinical trial guidelines
- Zero major regulatory violations in 2023
Collaborative Innovation
Strategic partnerships to accelerate neurological research.
| Research Collaborations | Partner Organizations |
|---|---|
| 7 active research partnerships | Academic institutions, pharmaceutical companies |
Sustainability and Corporate Responsibility
Commitment to environmental and social governance.
- 30% reduction in carbon emissions by 2025 target
- Diversity in leadership: 42% women in executive positions
Sage Therapeutics, Inc. (SAGE) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.